SOUTH SAN FRANCISCO, Calif.-Solazyme, Inc. the leading industrial biotechnology company producing renewable oil and bioproducts from microalgae, announced that Unilever has joined its Series D financing round as a strategic investor. The strategic investment by Unilever adds to the previously announced Series D round.
“Unilever products touch the lives of over 2 billion people every day. Solazyme’s tailored oils and bioproducts provide innovative and sustainable solutions across many of their well established product lines. Our technology compliments Unilever’s aggressive drive and commitment to deliver sustainable high performance products to consumers globally”
This strategic investment leverages the development potential of both companies in the personal care and nutritionals markets, incorporating Solazyme’s renewable oil technology platform within Unilever’s broad product portfolio and market access. Unilever, which has an existing R&D agreement with Solazyme, is working with Solazyme’s tailored renewable oils and has successfully tested these oils in current product formulations.
“Unilever products touch the lives of over 2 billion people every day. Solazyme’s tailored oils and bioproducts provide innovative and sustainable solutions across many of their well established product lines. Our technology compliments Unilever’s aggressive drive and commitment to deliver sustainable high performance products to consumers globally,” said Jonathan Wolfson, CEO and co-founder of Solazyme.
Phil Giesler, Innovation Director at Unilever Corporate Ventures commented, “Solazyme is clearly a leading company in the biomaterials space. Unilever has been working closely together with Solazyme for two years now and this investment will help us to broaden our partnership in new application areas. It will also help us to plan for how future developments in Solazyme’s technology platform will contribute to Unilever’s supply options and assist us in our sustainability vision.”
Unilever joined other strategic investors in the round including Bunge, a leading global agribusiness and food company; CTTV Investments LLC, the venture capital arm of Chevron Technology Ventures LLC; San-Ei Gen, a major Japanese manufacturer and distributor of food ingredients; Jay Precourt and Family; and Sir Richard Branson via the Roda Group. Braemer Energy Ventures and Morgan Stanley led the round, with all major existing investors from previous rounds participating, including Lightspeed Venture Partners, The Roda Group, Harris and Harris Group, VantagePoint Venture Partners and Zygote Ventures.
About Solazyme:
Solazyme, Inc. is a renewable oil and bioproducts company and the leader in algal biotechnology. Founded in 2003 and headquartered in South San Francisco, Solazyme’s unique technology allows algae to produce oil and biomaterials in standard fermentation facilities quickly, efficiently and at large scale. These oils and biomaterials are tailored not only for biofuel production, but also as replacements for fossil petroleum and plant oils in a diverse range of products running from clean fuels and chemicals to cosmetics and foods. Solazyme’s oils and fuels provide compelling solutions to increasingly complex issues of fuel scarcity, energy security and environmental impact while fitting cleanly into the pre-existing multi-trillion dollar fuel infrastructure. Solazyme’s investors among others include Braemar Energy Ventures, Harris & Harris Group, Lightspeed VenturePartners, The Roda Group, and VantagePoint Venture Partners. For more information, please visit our website: http://www.solazyme.com